Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance
- 25 October 2017
- journal article
- research article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 34 (3) , 238-242
Abstract
Background: Insulin resistance and obesity are not universal features of polycystic ovary syndrome (PCOS). We planned to assess the differences between patients with nonobese /insulin-sensitive phenotype vs. obese/ insulin-resistant phenotype in terms of the potential mechanisms underlying their hyperandrogenism. Materials and methods: A total of 52 women satisfying Androgen Excess Society (AES) criteria were included. Hormonal and metabolic profile including prolactin, dehydroepiandrosterone sulfate (DHEAS), free testosterone, sex hormone binding globulin (SHBG), fasting plasma glucose and insulin were measured in follicular phase. Results: DHEAS was found to be higher in the nonobese patients as compared to the obese (p = 0.01). There was also a strong trend for a higher DHEAS among patients with lower insulin resistance by homeostatic model assessment (HOMA-IR< 2.3) (p = .06).While the total testosterone (p = .044) and SHBG (p = .007) were found to be lower in the more insulin-resistant group (HOMA-IR ≥ 2.3), the free testosterone levels were similar. However, the percentage of free testosterone was higher in the more insulin-resistant group (p = .005). Conclusions: The hyperandrogenic state in PCOS appears to have heterogenous origins. Nonobese patients with PCOS have adrenal hyperandrogenism as the underlying mechanism while their obese/ insulin-resistant counterparts have low SHBG and hence an increased fraction of free testosterone.Keywords
Funding Information
- Tirumala Tirupati Devasthanams (TTD)
This publication has 37 references indexed in Scilit:
- Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysisHuman Reproduction Update, 2012
- Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteriaFertility and Sterility, 2010
- Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndromeFertility and Sterility, 2009
- The investigation and management of severe hyperandrogenism pre- and postmenopause: Non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metforminGynecological Endocrinology, 2008
- Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS)Clinical Endocrinology, 2005
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndromeFertility and Sterility, 2004
- Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndromeClinical Endocrinology, 1997
- Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancyMetabolism, 1994
- Pituitary-Ovarian Responses to Nafarelin Testing in the Polycystic Ovary SyndromeNew England Journal of Medicine, 1989
- Insulin Stimulates Androgen Accumulation in Incubations of Human Ovarian Stroma and ThecaObstetrics & Gynecology, 1984